BRAIN Initiative: New Technologies and Novel Approaches for Recording and Modulation in the Nervous System (R01 Clinical Trial Not Allowed)
Posted by National Institutes of Health
Opportunity snapshot. This Grants.gov announcement — BRAIN Initiative: New Technologies and Novel Approaches for Recording and Modulation in the Nervous System (R01 Clinical Trial Not Allowed) — is cataloged under number RFA-NS-25-018 and tied to CFDA assistance listing 93.173;93.213;93.242;93.273;93.279;93.286;93.853;93.865;93.866;93.867, posted by National Institutes of Health. Grants.gov currently shows the opportunity as open, first posted on September 24, 2024 and last updated on February 13, 2026. The funding category is Discretionary, delivered as a grant.
Award economics. The award range on file is Varies by applicant. Cost sharing is not required, so applicants do not need to commit matching funds to be competitive on this opportunity. Federal award ranges are often upper bounds; actual allocations reflect program appropriations, the strength of the applicant pool, and the evaluation committee's scoring.
Deadline and action path. Applications close on June 16, 2026 — roughly 11 days from today. That is a tight window — prioritize SAM.gov registration validation and assemble required documents immediately. Every Grants.gov submission requires an active SAM.gov registration and a Unique Entity ID. Review the Eligibility section below carefully — federal eligibility categories (nonprofit, state or local government, tribal, individual, educational institution, small business) have distinct registration and reporting requirements. Pre-application outreach to the listed agency contact is permitted and often welcomed — it helps clarify scope and scoring priorities.
Award Range
Varies by applicant
Close Date
June 16, 2026
Posted
September 24, 2024
Instrument
Grant
Description
This Notice of Funding Opportunity (NOFO) seeks applications for proof-of-concept testing and development of new technologies and novel approaches for recording and modulation of neural cells and circuits, to address major challenges and enable transformative understanding of dynamic signaling in the central nervous system. Preliminary feasibility data are not required, and it is expected that the proposed research may be high-risk, but if successful could profoundly change the course of neuroscience research. Applications may propose development of instrumentation hardware and/or devices and associated software, and/or molecular constructs for sensing and manipulating neural activity. Approaches may utilize any modality such as optical, electrical, magnetic, or acoustic recording/manipulation, to target neuronal electrical signals or other forms of neural activity, including intracellular signaling and engagement of non-neuronal cells in circuit function. A companion NOFO (RFA-NS-25-017) is targeted to projects focused on optimization of instrumentation and devices that are later in the development cycle, where iterative optimization and end-user testing is needed. The companion NOFO does not allow projects primarily focused on development or optimization of molecular constructs for recording and manipulating neural activity. Projects of this nature are supported by this NOFO and other BRAIN Initiative announcements including RFA-MH-22-245, RFA-MH-21-175, and RFA-EY-21-001 (or their reissue). For this and the companion NOFO, the aim of the proposed technologies should be to reduce major barriers to conducting neurobiological experiments, including considerations of cost and ease of access, and to enable new discoveries for understanding neural circuit function. Technologies should address major challenges associated with recording and modulating CNS activity, at cellular or circuit resolution, and should contribute to an overall ecosystem of technologies spanning multiple spatial and temporal scales in any region throughout the CNS. The approaches should be compatible with experiments in behaving animals, with an expectation that they will be validated with in vivo experiments during the course of the project. Proposed validation experiments must focus on demonstrating the capabilities and potential impact of the technology, rather than advancing the state of biological knowledge as the primary project goal. Applications are encouraged to integrate multiple approaches, and where appropriate, to leverage a variety of domains of expertise from biological, chemical, and physical sciences, engineering, computational modeling, and statistical analysis.
Eligibility
00;01;02;04;05;06;07;08;11;12;13;20;22;23;25
Official Listing on Grants.gov
View full details, application forms, and submission instructions.
Agency Contact
NIH Grants Information <br/>grantsinfo@nih.gov
Key Dates
Frequently Asked Questions
What is this grant opportunity?
Is this opportunity still open?
How much funding is available?
How do I apply?
More from National Institutes of Health
Clinical Coordinating Center for Multi-Site Investigator-Initiated Clinical Trials (Collaborative UG3/UH3 Clinical Trial Required)
Single-Site Investigator-Initiated Clinical Trials (R61/R33 Clinical Trial Required)
Data Coordinating Center for Multi-Site Investigator-Initiated Clinical Trials (Collaborative U24 Clinical Trial Required)
Development of Collaborative Research Facilities or Research-Resource Facilities (C06 Clinical Trial Not Allowed)
Research Grants in Clinical Informatics (R01 Clinical Trial Optional)
Disclaimer: This information is sourced from Grants.gov and SAM.gov and is for informational purposes only. Opportunity details, deadlines, and eligibility requirements change frequently. Always verify current information directly on Grants.gov before applying. PlainGrants is not affiliated with any federal agency.
Read our methodology — how this data is sourced, computed, and verified.
Related
| Publisher | Kiznis Studio |
| Sources | Public official public datasets |